An EGFRvIII peptide fragment
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

EGFRvIII Peptide (trifluoroacetate salt)

Item No. 38846

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-leucyl-L-α-glutamyl-L-α-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valine, trifluoroacetate salt
Synonyms
  • Epidermal Growth Factor Receptor Variant III Peptide
  • PEGFRvIII (9-mer)
Molecular Formula
C48H78N12O16 • XCF3COOH
Formula Weight
1079.2
Purity
≥98%
Formulation (Request formulation change)
A solid
Peptide Sequence
LEEKKGNYV-OH
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 10 mg/mlPBS (pH 7.2): 10 mg/ml
SMILES
[H]N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](C(C)C)C(O)=O)=O)CC1=CC=C(O)C=C1)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C48H78N12O16.C2HF3O2/c1-25(2)21-29(51)41(68)55-32(15-17-38(64)65)44(71)58-33(16-18-39(66)67)45(72)57-31(10-6-8-20-50)43(70)56-30(9-5-7-19-49)42(69)53-24-37(63)54-35(23-36(52)62)46(73)59-34(22-27-11-13-28(61)14-12-27)47(74)60-40(26(3)4)48(75)76;3-2(4,5)1(6)7/h11-14,25-26,29-35,40,61H,5-10,15-24,49-51H2,1-4H3,(H2,52,62)(H,53,69)(H,54,63)(H,55,68)(H,56,70)(H,57,72)(H,58,71)(H,59,73)(H,60,74)(H,64,65)(H,66,67)(H,75,76);(H,6,7)/t29-,30-,31-,32-,33-,34-,35-,40-;/m0./s1
InChi Key
ISEFQCPJYZXSNS-LVRFVWIISA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $31

    Add

    5 mg

    $147

    Add

    10 mg

    $278

    Add

    25 mg

    $539

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    EGFRvIII peptide is a synthetic peptide that corresponds to the fusion junction of EGFRvIII, a tumor-specific, constitutively active variant of EGFR that lacks amino acids 6-273 of wild-type EGFR.1,2 It binds to MHC class I subtype HLA-A*0201-positive T2 cells when used at a concentration of 25 µg/ml.1 EGFRvIII peptide induces antigen presentation in dendritic cells derived from isolated human peripheral blood mononuclear cells (PBMCs), which stimulates activation of, and IFN-γ production by, CD8+ cytotoxic T lymphocytes. Immunization with EGFRvIII peptide (15 µg/animal), in combination with the toll-like receptor 5 (TLR5) agonist flagellin B, increases the number of CD8+ T cells and decreases the number of regulatory T cells (Tregs) in the brain, reduces tumor volume, and increases survival rate in an orthotopic GL261 glioblastoma mouse xenograft model.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Wu, A., Xiao, J., Anker, L., et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J. Neurooncol. 76(1), 23-30 (2006).

    2. Choi, J.M., Lim, S.-H., Liu, Z.-P., et al. Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model. BMC Cancer 22(1), 986 (2022).